Cycurion, Inc. Form 8-K Summary
Business Context and Reporting Period
Cycurion, Inc. (NASDAQ: CYCU), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on August 3, 2026, regarding events occurring on July 30, 2026. The filing details a warrant inducement transaction designed to raise capital through the exercise of existing warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: The Company expects to receive approximately $4.5 million in gross proceeds from the exercise of existing warrants.
- Shares Exercised: 3,341,439 shares of common stock underlying existing warrants were exercised.
- Exercise Price Adjustment: The exercise price for the existing warrants was reduced from $3.62 per share to $1.35 per share solely for this transaction.
- New Securities Issued: The Company issued 5,012,159 new unregistered warrants (representing 150% of the exercised shares) with an exercise price of $1.65 per share.
- Transaction Costs: The Company agreed to pay a financial advisory fee of 6.0% of gross proceeds plus a $200,000 fee for prior services, and legal expense reimbursement up to $45,000.
Material Changes and Transaction Mechanics
The primary material change is the entry into a Warrant Inducement Agreement with a holder. This agreement facilitated the immediate cash exercise of existing warrants issued on December 5, 2025. In exchange for the immediate exercise, the holder received new warrants with a lower exercise price ($1.65) compared to the original warrant price ($3.62) and the induced exercise price ($1.35). The new warrants are subject to stockholder approval for exercisability under Nasdaq rules and contain anti-dilution adjustments and beneficial ownership limitations of 4.99% (increasable to 9.99%).
Outlook, Risks, and Contingencies
- Registration Obligation: The Company must file a registration statement for the resale of shares issuable upon exercise of the New Warrants within 90 calendar days of July 30, 2026.
- Stockholder Approval: The New Warrants will not become exercisable until stockholder approval is obtained as required by applicable Nasdaq rules.
- Dilution Risk: The issuance of 5,012,159 new warrants represents a significant potential dilution to existing shareholders, subject to the 4.99% beneficial ownership limitation.
- Liquidity: The transaction is expected to improve immediate liquidity with the anticipated $4.5 million in gross proceeds, net of advisory fees and expenses.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting the 6.0% advisory fee, the $200,000 prior service fee, and legal reimbursements.
- Confirm the timeline for obtaining the required stockholder approval to make the New Warrants exercisable.
- Review the full text of the Warrant Inducement Agreement (Exhibit 10.1) for specific anti-dilution adjustment formulas and beneficial ownership limitation mechanics.
- Monitor the filing of the registration statement for the New Warrants within the mandated 90-day window.